Perspectum Medical Education Hub

Oxford February 24th 2021. In a new study, Perspectum’s LiverMultiScan® outperformed other markers of liver stiffness for identifying high risk NASH patients, encouraging its use as a non-invasive alternative to biopsy in clinical care and drug development. Non-alcoholic fatty liver disease (NAFLD) affects up to 25% of the population worldwide. 20% of these cases progress […]

Research led by Professor Jonathan Fallowfield, Chair of Translational Liver Research at University of Edinburgh, in collaboration with GlaxoSmithKline, showed that multiparametric MRI can be used to assess liver tissue characteristics in preclinical drug testing for Non-alcoholic Fatty Liver Disease (NAFLD). The method showed good diagnostic accuracy in animal models of liver disease and correlated […]

Oxford, United Kingdom, February 4th, 2021. A recent study demonstrates the potential for non-invasive measures of liver fibro-inflammation and fat, provided by Perspectum’s LiverMultiScan®, to detect pharmacodynamic changes in non-alcoholic steatohepatitis (NASH), potentially offering a safe alternative to liver biopsy for late-stage clinical trials. Non-alcoholic fatty liver disease (NAFLD) and its more severe sub-type, NASH, […]

UK Biobank is a major national and international health resource, and a registered charity in its own right. UK Biobank’s aim is to improve the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses.  A study by Perspectum Diagnostics using UK Biobank data has revealed that the prevalence of non-alcoholic steatohepatitis […]

CHARLOTTESVILLE, 2 February 2021 – UVA Health is now offering patients a non-invasive liver imaging test, LiverMultiScan, to assess fatty liver disease. Patients who are obese, as well as patients with type 1 and type 2 diabetes, are at greater risk for non-alcoholic fatty liver disease (NAFLD), a chronic liver condition characterized by the accumulation […]

Perspectum Diagnostics today revealed new data which indicates that the prevalence of non-alcoholic steatohepatitis (NASH) among UK adults could be as high as 12%. NASH is a progressive form of non-alcoholic fatty liver disease (NAFLD) which is now considered to be one of the major causes of cirrhosis of the liver. Perspectum Diagnostics today revealed […]

Oxford, UK, January 14, 2021. The UK’s Medicines & Healthcare products Regulatory Agency (MHRA) approved the use of CoverScan MD, an MRI-based technology that maps the effects of COVID-19 on several of the body’s key organs, developed by Perspectum. With 1 in 20 COVID-19 patients predicted to experience ongoing symptoms, or “Long COVID”, CoverScan MD […]

Dallas, Texas, December 14, 2020 – The Food and Drug Administration (FDA) Center for Drug Evaluation and Research has granted Perspectum funding to accelerate the qualification of their proprietary imaging biomarker, cT1, as a drug development tool for liver disease. The study will be run at Massachusetts General Hospital.     An estimated 30 percent […]

We are delighted to announce that LiverMultiScan™ has received FDA 510(k) clearance for the next release of the software. Read the full press release below: FDA Clearance For Perspectum Diagnostics’ LiverMultiScan™ Means More Patients Can Benefit From Access To State-Of-The-Art Non-Invasive Diagnostic Aid For Liver Disorders. Oxford, United Kingdom, Monday November 27, 2017: Perspectum Diagnostics […]

Oxford December 9th, 2020. The growing need for cost-effective non-invasive tools to diagnose fatty liver disease and reduce the number of painful, costly and risky liver biopsies is being addressed by Perspectum’s RADIcAL1 trial, as outlined in the recently published research protocol. The prevalence of non-alcoholic fatty liver disease (NAFLD) and the more aggressive subtype, […]

A pioneering European research project aims to lead to new diagnostic tests to assess patients with non-alcoholic fatty liver disease (NAFLD) and identify those most at risk for developing severe inflammation and liver scarring. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) funded by the European Innovative Medicines Initiative 2 Joint Undertaking, brings together clinicians […]

With AASLD 2020: The Liver Meeting Digital Experience (TLMdX) having come to a close, we spent some time with catch-up Marija Mavar, co-lead of our Pharma Solutions business unit, and Dr. Andrea Dennis, Head of Biomarker Science, to hear their thoughts. In this Q&A, we take a deep dive into their experience at this year’s […]

In this episode of the AWS Health Innovation Podcast, Amrita Sarkar, Principal Healthcare and Life Sciences Startups Business Development Manager at Amazon Web Services, sits down with Rajarshi Banerjee, aka ‘Banjo’, the CEO of Perspectum. a company revolutionizing the way we diagnose and monitor chronic diseases. Perspectum’s medical imaging software applies artificial intelligence to enhance MRI […]

Oxford December 2nd, 2020. A newly published study on patients with primary and secondary liver cancer shows how Perspectum’s non-invasive MRI technology can help predict those at increased risk of poor surgical outcomes, potentially reducing healthcare costs by shortening length of hospital stay. The new technology, Hepatica, seamlessly integrates into routine pre-operative MRI assessment and […]

Dallas, USA, November 26, 2020. New data will be presented by Perspectum at this year’s RSNA meeting. Perspectum will be showcasing AI-powered whole-image quantitative liver fat measurement for hepatic fat without a biopsy. The fully automatic analysis excludes liver structures that can confound other ways of measuring liver fat and has been developed within Perspectum’s […]

WASHINGTON & OXFORD, England (BUSINESS WIRE) Perspectum announced two research studies that were recently published, bringing hope to people withmetabolic dysfunction-associated steatohepatitis (MASH). This research affirms the utility of quantitative MRI imaging as an alternative to liver biopsy insome clinical trials and in patient care management. The first study shows how noninvasive quantitative MRI scans can identify […]

Reversing fatty liver disease; New study in Hong Kong will use state-of-the-art clinical technology to evaluate different weight-loss methods Singapore November 18, 2020. Researchers at The Chinese University of Hong Kong and Prince of Wales Hospital, in collaboration with Perspectum, will use LiverMultiScan®, a new clinically available MRI-based technology, to evaluate how well different weight-loss […]

CoverScan, Perspectum’s multi-organ MRI technology, has been nominated for the 2024 Prix Galien USA award for Best Digital Health Solution. Perspectum is among nominees who have been recognized for “extraordinary dedication to innovation” to advance patient care. Winners will be announced during thePrix Galien USA Forum on November 7, 2024, at the Alexandria Center for […]

CHRISTUS Shreveport-Bossier Health System are pleased to announce a groundbreaking partnership with Perspectum, a leading provider of medical imaging solutions, that gives doctors and patients in north Louisiana access to the latest diagnostic aids to help improve the clinical journey for patients with liver disease. CHRISTUS Shreveport-Bossier will leverage Perspectum’s new LiverMultiScan, a non-invasive test that can assess liver health using a comprehensive non-contrast MRI to scan for […]

Boston, USA, November 10, 2020. Perspectum®, a leading imaging technology company and imaging CRO, elevates their service offering for clinical trials with the launch of Atlas for non-invasive, multi-organ characterization of disease. As many as 1 in 4 Americans suffer from chronic liver disease and may experience clinical complications affecting other organs. Atlas is a […]

WASHINGTON, D.C. — November 14, 2024 – (BUSINESS WIRE) — Perspectum, a leader in medical imaging quantification techniques, today announced that it has been awarded a 2024 U.S. Food and Drug Administration Drug Development Tool (DDT) Research Grant to evaluate a novel biomarker aimed at addressing the unmet needs of patients with rare diseases. This […]

San Francisco, October 20 2020: Perspectum’s new whitepaper clearly outlines how the upfront cost of pre-screening subjects for NASH clinical trial enrollment with non-invasive, MRI-based imaging biomarkers can be significantly offset by the costs saved due to the reduction in total number of biopsies required for trial enrollment. Non-alcoholic steatohepatitis (NASH) presents a major challenge […]

WASHINGTON, D.C. – MARCH 18, 2025 – (BUSINESS WIRE) – Perspectum today released the results of a multinational study showing that LiverMultiScan can reduce liver biopsies, lead to fewer specialist consultations, and improve the rate of diagnosis for patients with metabolic dysfunction- associated steatotic liver disease (MASLD). The groundbreaking study was published in Nature Communications […]

Would you, or someone you care about benefit from a free, state-of-the-art liver test?   Perspectum is offering a free LiverMultiScan MRI for individuals in select cities. Why is it important to get your liver checked? Millions of people across the world are affected by a silent disease (Fatty Liver Disease) that is damaging their […]

Oxford October 6th, 2020. State-of-the-art non-invasive multiparametric MRI could offer new possibilities for monitoring and treatment of autoimmune hepatitis (AIH) in children, potentially reducing unnecessary biopsies, shows the latest study by Perspectum. Autoimmune hepatitis (AIH) affects patients throughout their entire lives. This chronic disease occurs when the body’s immune system attacks the liver cells causing […]

WASHINGTON – Nature Medicine today published a study showing that Perspectum’s iron corrected T1, or cT1, predicts liver-related and cardiac outcomes, including morbidity. Liver disease is a modifiable cardiac risk factor, and this study confirmed that it can be quantified with MRI cT1. “The results confirm previous observations of the liver being an early warning […]

Oxford September 24th, 2020. The link between a specific genetic marker and severity of non-alcoholic fatty liver disease (NAFLD) has been validated in this study by researchers from several institutions and organisations, including Perspectum and the UK Biobank. This will help to better identify individuals at increased risk of more advanced forms of the disease. […]

Perspectum is proud to see one of our commercial collaborations reach a major milestone, with results from an early-phase clinical trial now published in The Lancet. This study, led by Marea Therapeutics, evaluated the safety and efficacy of MAR001, a novel monoclonal antibody targeting angiopoietin-related protein 4 (ANGPTL4), in participants with metabolic dysfunction. Genetic studies […]

Medical Imaging plays an important role in the clinical development of new drugs. In non-alcoholic steatohepatitis (NASH) specifically, it is one of the most common primary and surrogate endpoints. Liver biopsy is currently the reference standard to discriminate between hepatic steatosis and steatohepatitis, but has the inherent limitations of being invasive, expensive, and often imprecise.1 […]

UK Biobank has marked the successful completion of the world’s largest human imaging study, with over 60,000 participants scanned as part of its landmark research programme. The celebration highlighted the power of large-scale imaging for advancing healthcare. Below, you can also watch our CEO, Dr Rajarshi Banerjee, sharing insights in his talk at the event. […]

Oxford September 22nd, 2020. Latest research from Perspectum shows how a new non-invasive combined imaging and blood biomarker could accurately identify NASH in NAFLD patients, highlighting its benefits for screening in clinical trials. Non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD), is a life-threatening disease with currently no approved drugs […]

Perspectum is a proud sponsor and supporter of the Global Liver Institute‘s Beyond the Biopsy initiative and its mission to accelerate the acceptance and adoption of noninvasive technologies as an alternative to biopsy.   Tune in to virtual panels with leading experts, policymakers, and patient advocates starting September 9th. GLI LIVE Beyond the Biopsy Panels […]

WASHINGTON, D.C. – SEPTEMBER 03, 2025 – (BUSINESS WIRE) – Newly published economic modeling concludes that Perspectum’s proprietary biomarker cT1 may help US Veterans Administration (VA) health care enrollees gain better access and treatment for MASH (metabolic dysfunction-associated steatohepatitis), an advanced stage of MASLD (metabolic dysfunction-associated steatotic liver disease). Hancock et al’s study, published in […]

Dallas, Texas, August 18, 2020 – Perspectum® is proud to announce a collaboration with UT Southwestern Medical Center, to include LiverMultiScan® technology in the Dallas Heart & Minds Study (DHMS). DHMS initial aim was to improve the diagnosis, prevention and treatment of heart disease, over the years this has expanded to encompass metabolic diseases, such […]

Oxford, August 7th, 2020. A review of techniques for clinical decision making in diffuse liver disease, published this week in Abdominal Radiology, highlights the potential for multiparametric MRI (mpMRI) to transform clinical practice. Chronic liver disease leads to progressive injury from aetiologies such as iron overload, steatosis, steatohepatitis, viral hepatitis, autoimmune, metabolic disease and some […]

Oxford, September 4th, 2020. The first European guidance using multiparametric MRI (mpMRI), including cT1® , to assess the risk of liver fibrosis and inflammation in patients suspected of NAFLD has been published,  helping to improve clinical management and treatment monitoring. Non-alcoholic fatty liver disease (NAFLD) is the excessive accumulation of fat in the liver due […]

Our mission is to improve the lives of patients. We do this by building best-in-class technologies and working collaboratively with our customers to bring those solutions to patients. To ensure you can deliver the best care to patients, we have a dedicated team focused on customer success; meet the Madison’s. By joining forces, they provide […]

Oxford, UK – September 2021. Perspectum®’s LiverMultiScan® significantly enhanced patient understanding of chronic liver disease (CLD) care in a first-of-its-kind study published in the Journal of Patient-Reported Outcomes, highlighting how it can help improve adherence to lifestyle interventions. Using a qualitative, interview-based approach, patients with CLD reported their first-hand experiences and perceptions of how LiverMultiScan’s […]

Oxford, August 6th, 2020. Perspectum’s cT1® is the best non-invasive predictor of clinical outcomes in chronic liver disease (CLD) patients, new research published in Liver International finds. As chronic liver disease (CLD) prevalence is at a public health crisis level, the ability to accurately and reliably identify those patients most at risk of poor clinical […]

San Francisco, CA – September 16, 2021 – Perspectum, a global quantitative and genomics-based imaging company, is joining forces with Datavant, the leader in helping healthcare organizations securely connect health data, to offer pharma-sponsored clinical trial recruitment solutions. The partnership with Datavant will enable Perspectum to connect its precision quantitative and genomics-based imaging data to […]

Oxford, July 23, 2020. A review of screening modalities and treatment options for individuals with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) published in Diabetic Medicine puts a spotlight on the link between these two diseases. NAFLD is a spectrum of conditions ranging from excess liver fat, to inflammation, fibrosis, cirrhosis and end-stage […]

San Francisco, Oxford, July 15, 2020. Perspectum, a leading medical imaging company, has begun work on expanding its offering by including cardiac and lung imaging in many new research projects, specifically in Coronavirus multiorgan imaging studies. Recently launched COVERSCAN and Modify are two such studies, which involve aortic and cardiac imaging using Magnetic Resonance Imaging […]

Dallas, TX., October 4, 2021. More than 100 million people in the United States have liver diseases and thousands die each year from chronic liver disease.  But if diagnosed early it may be possible to halt or even reverse liver disease progression.  Today we are announcing that West Jefferson Medical Center is now offering access […]

Dallas, Texas, July 7, 2020 – Perspectum is collaborating with top medical institutions to evaluate the diagnostic performance of their flagship product, LiverMultiScan®, at identifying eligible patients with non-alcoholic steatohepatitis (NASH) for enrollment into clinical trials. LiverMultiScan is a non-invasive MR imaging solution for quantitative characterization of liver tissue that could help sponsors both accelerate […]

Partnership Combines Imaging and Functional Assessment for Clinical Research San Francisco, CA and Denver, CO – Nov. 1, 2021. Perspectum and HepQuant are proud to announce a strategic business partnership to provide seamless delivery of HepQuant’s liver function assessment technology via Perspectum’s Contract Research Organization (CRO) services. The collaboration will enable pharmaceutical companies sponsoring clinical […]

Oxford, England, 3rd July 2020 Perspectum are proud to announce a new partnership to improve the lives of patients with liver disease by providing earlier and more accurate diagnoses. The collaboration with Manchester and Nottingham Universities, as well as Roche Diagnostics, GE Healthcare and Jiva.AI will accelerate development of AI solutions for liver disease diagnostics. […]

Oxford, Jun 21, 2020. High liver fat is associated with a higher risk of developing more severe COVID-19 infection, new research finds. Scientists from Perspectum, using UK BioBank data, have revealed that obese patients with a fatty liver were at increased risk of developing symptomatic COVID-19 infection. Obese patients with normal liver fat showed no […]

OXFORD, England – January 2022. A new meta-analysis study published in the peer-reviewed journal, Clinical Gastroenterology and Hepatology, found that LiverMultiScan® cT1 (corrected T1) – a novel, MRI-based clinically relevant biomarker – can accurately identify patients with non-alcoholic steatohepatitis (NASH) who are at a high risk of disease progression. Several prior studies have shown that […]

San Francisco, January 27, 2022. Perspectum announced recruitment of the first patient in a multi-center collaborative study to characterize Primary Sclerosing Cholangitis  in children, “Prospective Observational Study of Primary Sclerosing Cholangitis (PSC) in Children”. This 10-year collaborative study includes 12 geographically-diverse children’s hospitals in the United States and one Canadian children’s hospital. Perspectum, through a […]

OXFORD, England – March 21, 2022. A first-of-its-kind study published in eClinicalMedicine – The Lancet, found that LiverMultiScan cT1 (an MRI-derived non-invasive tissue biomarker), improved autoimmune hepatitis (AIH) management by identifying patients in biochemical remission as well as patients in deep remission, with undetected, active sub-clinical disease at a high risk of disease relapse. AIH […]

Health economics study estimates significant savings for England’s NHS Oxford, U.K. — September 21, 2022. A health economic study performed by NHS England’s Oxford Academic Health Science Network (AHSN) showed that Perspectum’s LiverMultiScan — an artificial intelligence-enhanced, noninvasive liver health diagnostic tool — is a cost-effective alternative to painful, invasive liver biopsies for monitoring disease […]

Dallas, TX – September 27, 2022. Perspectum today announced The Food and Drug Administration (FDA) awarded the company a major grant to support the qualification of Perspectum’s imaging biomarker — cT1 — for diagnostic enrichment to reduce liver biopsy in clinical trials. Perspectum’s artificial intelligence-enhanced LiverMultiScan software, provides cT1, a quantitative biomarker for noninvasive identification […]

CHICAGO, IL Nov. 28, 2022 — Perspectum and Nuance Communications, Inc., a Microsoft company, announced today at the 108th Radiological Society of North America’s (RSNA) Annual Meeting (RSNA Booth #7938) their collaboration to deliver at scale Perspectum’s integrated digital platform suite for metabolic disease care and management. This new collaboration will help accelerate adoption of […]

Boston, MA and Monterrey, Mexico – 17 December 2025. Perspectum, a global medical technology company advancing quantitative imaging for metabolic, liver and multi-organ health, today announced a strategic partnership with Avant Santé, a patient-centric contract research organization (CRO) headquartered in Monterrey, Mexico, to support clinical research programs across metabolic health and liver disease for sponsors […]

Oxford, UK Nov. 24, 2022 – Perspectum is pleased to announce that Precious Medical Centre is expanding multiparametric diagnostic imaging services in the region by adding two new MRI scanners enabled with Perspectum’s Software as a Service  (Saas) LiverMultiScan product. Precious Medical Centre is a long-standing Perspectum partner and was the first in the region […]

Perspectum and InHealth have announced a new national diagnostics partnership that will significantly expand access to advanced MRI and increase capacity at the Oxford Community Diagnostic Centre (CDC). The Oxford CDC, one of NHS England’s leading sites, served more than 60,000 patients this year, a figure expected to climb to over 100,000 by 2027 through […]

Oxford, UK/Dallas, TX, January 5, 2023 – Perspectum, a precision health company which develops medical imaging tools to improve the diagnoses of metabolic diseases and cancer, has completed the first close of its Series C funding round. The new $36 million investment was led by Oppenheimer Holdings. The Series C funding brings the total amount […]

Dr. Rajarshi Banerjee is no longer with Perspectum. The Board has appointed the Company’s Chief Operating Officer, Dr. Rexford Newbould, as Interim Chief Executive Officer, alongside Dr. Mike Rosenblatt who will assume the role of Executive Chair. The Board and executive leadership team remain confident in the company’s direction and dedication to improving patient care.  Perspectum’s strategy, […]

Perspectum Completes $19 Million Second Close of Series C Funding Led by Oppenheimer & Co. Inc. (“Oppenheimer”) Oxford, UK/Dallas, TX, March 15, 2023 – Perspectum, a precision health company which develops medical imaging tools to improve the diagnoses of metabolic diseases and cancer, has completed the second close of its $55 million Series C funding […]

San Francisco, CA – April. 13, 2023. Perspectum is proud to announce a strategic collaboration with Singapore-based BluMaiden Biosciences. Developed to identify biomarkers and small molecule therapeutics from within the human microbiome, BluMaiden Bioscience’s platform-based AI technologies will be offered alongside Perspectum’s medical imaging solutions. The collaboration is aimed at transforming the pharmaceutical clinical trial […]

Oxford, 26 June, 2023 ‍ Liver disease, the UK’s third leading cause of premature death, poses a significantly greater threat to human health than previously recognized. Ground-breaking new Perspectum research using Magnetic Resonance Imaging (MRI) AI-enabled assessment tools has revealed that patients with liver disease are at considerably higher risk of heart failure and other […]

Dallas, Texas – Effective March 13, 2022. AIM Specialty Health deems LiverMultiScan® medically necessary for evaluating diffuse liver diseases, covering over 77 million US lives. This new AIM Advanced Imaging guideline includes the stand-alone CPT Code 0648T used when billing for the LiverMultiScan procedure. “These advances in coverage and reimbursement for LiverMultiScan procedures have the […]

Perspectum’s CoverScan Obtains FDA Clearance; Builds on Recent UKCA Marking, Oxford, United Kingdom, May 25, 2022 — On May 19, 2022, the United States Food and Drug Administration (FDA) granted 510(k) clearance to Perspectum’s CoverScan, a noninvasive multiparametric advanced cloud-based software suite that provides comprehensive assessments of six organs, including the heart, liver, lungs, kidneys, […]

Did you know millions of people across the world are affected by a silent disease that is damaging their internal organs and often goes undetected until it is too late? Nonalcoholic Steatohepatitis (NASH) is a potentially fatal condition affecting up to 12% of adults worldwide, an estimated 115 million people around the globe. That’s why […]

As the prevalence of NAFLD continues to grow and the risk for NASH is significantly increased in patients with type 2 diabetes, it is important to screen all those in whom NASH is a clinically possibility (e.g. elevated ALT, evidence of fatty liver, etc.). Quick Facts:   We have created LiverMultiScan to combat the rising […]

We’ve launched an educational and engaging provider education series as part of our continuing educational efforts during COVID-19: #1: How We Aid Doctors in the Diagnosis of Liver Disease #2: Your Questions Answered- Clinical FAQ’S #3: LiverMultiScan for Endocrinologists #4: Collaborating for Better Outcomes

We are proud to share that our co-founder, Sir Michael Brady, has been elected to the National Academy of Engineering (NAE). Election to the NAE is among the highest professional distinctions awarded to an engineer. Michael has been recognised for his contributions to vision-based robotics and image-based medical diagnosis and treatment. His pioneering work helped […]

Clinical trial participants have been asking whether it is safe to get an MRI scan during the COVID-19 outbreak. New guidance for health systems was released over the weekend on resuming elective procedures. Our aim is to provide some additional guidance for sponsors running clinical trials in order to mitigate the impact of the COVID-19 […]

Read our answers to frequently asked questions about LiverMultiScan. You might be wondering: Will it be approved by insurance? Reimbursement for an abdominal MRI may fall under clinical indications when there is evidence of advanced fibrosis, high-risk features or other clinical indications as determined by insurance providers. What will LiverMultiScan be useful for? LiverMultiScan can […]

Oxford, 21st April 2020. Perspectum, the leading medical imaging company, is launching the first study to map how COVID-19 impacts the health of multiple organs and identify at-risk features for the virus, with detailed cross-sectional imaging and genetic studies. This study has received approval following expedited ethics review. The primary objective is to determine the […]

Perspectum delivers cutting-edge digital technologies that help clinicians provide better care for patients with liver diseases. With a strong focus on conditions that affect the liver, our vision is to empower patients and clinicians — through quantitative imaging metrics that provide greater insight on liver health and disease — enabling early detection, diagnosis, and targeted […]

Oxford, 14 April 2020. Perspectum® (“Perspectum” or “the Company”) a medical software company that provides non-invasive technology for identifying and monitoring multiple diseases announced today the completion of a $36M financing from new and existing investors. The company’s first diagnostic product (LiverMultiScan®) uses software to extract quantitative data from current MRI scans to aid with […]

Obesity is the biggest single chronic risk factor for hospital admission in patients under 60, increasing the risk 2-3-fold. Data from the CDC, supported by clinical studies in China, Europe and now New York have shown that raised liver enzymes and high blood pressure also add risk, suggesting that over 70 million Americans with obesity, […]

Leading the Charge Against One of USA’s Most Common Undiagnosed Pre-Existing Health Conditions Dallas, Texas, April 9, 2020- Perspectum, a medical imaging company developing innovative software to improve outcomes of patients with metabolic disease and cancer, is pleased to announce a partnership with 3T Radiology & Research, a medical diagnostic imaging center in Aventura, Florida.  […]

Identification of a gene associated with fibro-inflammatory liver disease could lead to the development of new drugs to prevent the disease in at-risk patients. With the worldwide emergence of obesity-related conditions such as type 2 diabetes and heavy alcohol consumption, non-alcoholic and alcoholic fatty liver diseases (NAFLD and AFLD) are increasingly common. This timely research […]

Better serve your patients. LiverMultiScan, a non-invasive MRI technology, helps aid diagnosis of liver disease. LiverMultiScan has demonstrated accuracy and best-in-class repeatability — giving added confidence to clinicians who are assessing changes in their patients’ liver tissue health. LiverMultiScan provides measures that can be used to assess a wide variety of liver disorders. It characterizes […]

Oxford, 11th March, 2020. A new tool providing accurate and precise measurements over the entire biliary tree could address unmet needs in biliary diseases, latest research shows. The study published by Perspectum in the Journal of Magnetic Resonance Imaging demonstrates how the ground-breaking software, MRCP+, can process a routine non-invasive MRI scan to provide state-of-the-art […]

Dallas, TX, February 26, 2020. Stand-Up MRI of Miami and Perspectum have partnered to deliver to their local community, the latest in diagnostic technology for fatty liver disease. Patients in South Florida will be able to benefit from the non-invasive technology, LiverMultiScan, which will help their physicians make a more detailed assessment of their liver […]

Oxford 31st January 2020. The burden of diseases related to obesity and fatty liver disease can be reduced using a simple structured approach to diet and physical activity — as demonstrated in a Gastroenterology Clinics paper co-authored by Perspectum employee, Thomas Waddell, and CEO, Rajarshi Banerjee. In fact, only a small reduction in body weight […]

Perspectum are honoured to announce that their employee, Lis Pickles, has been awarded the prestigious Royal Commission for the Exhibition of 1851 Industrial Fellowship to pursue doctoral studies in joint collaboration with Perspectum and Oxford University’s Institute of Biomedical Engineering. Lis’s research aims to address a major unmet need to improve the detection and treatment […]

Oxford, 14 Nov 2019. Perspectum will be showcasing the application of Artificial Intelligence in their FDA-cleared, quantitative imaging services — LiverMultiScan for liver tissue characterization and MRCP+ for biliary tree visualization — at RSNA’s annual meeting this year. Perspectum’s co-founder, Professor Sir Michael Brady, will show how machine learning can be integrated with LiverMultiScan and […]

Oxford, UK; October 30, 2019. Perspectum Diagnostics is excited to unveil new data at The Liver Meeting® 2019, highlighting the diagnostic capabilities of their FDA-cleared imaging products. Showcasing their flagship product, LiverMultiScan—new data from Asia, Europe, and North America reveals its potential to reduce the need for liver biopsies, advance clinical care and improve quality […]

Singapore, 10 October 2019. Perspectum, the leading provider of diagnostic solutions for metabolic disease and cancer, is partnering Precious Medical, a premier imaging centre in Singapore, following a successful launch event this week. Chronic liver disease is a ‘silent’ and growing epidemic. Increasing levels of obesity and diabetes have driven a rise in non-alcoholic fatty […]

Dallas, TX, September 17, 2019. The Food and Drug Administration (FDA) has awarded Perspectum Inc $250,000 to qualify its proprietary biomarkers for NASH in collaboration with Dr. Naim Alkhouri at the Texas Liver Institute. These funds have been awarded under the Drug Development Tool Research Grant (U01). The study will qualify the imaging markers cT1 […]

Oxford, UK, Sep 12 2019. Funded by Innovate UK and in partnership with Dr Palak Trivedi at University of Birmingham and University Hospitals Birmingham, and Oxford Academic Health Science Network, Perspectum has initiated a study to establish the clinical utility of MRCP+, a new quantitative imaging tool for biliary disease. MRCP is considered the ‘gold […]

Dallas, TX, USA, 20 August 2019. Combining the best in imaging and pathology—Europe’s fastest-growing life science company, Perspectum, joins forces with a premier provider of pathology services, ProPath. This partnership will enable pharmaceutical companies running clinical trials for liver disease, including NAFLD and NASH, to receive both pathology and imaging expertise from one CRO. For […]

Oxford, UK, July 24, 2019. A study into the mechanism behind liver iron accumulation confirms three genes are responsible for iron overload in the liver. High liver iron, often referred to as the Celtic Curse, is very common in the Irish population with as many as 1 in 8 suffering from this disease. Previous research […]

Oxford, UK, 11th April 2019. SC Liver Research Consortium (SC Liver) and Perspectum Diagnostics have developed a major US-based clinical network to provide clinical trial services that support the development of drugs for liver disorders. This project has enabled several private clinical sites and large academic centers sites for clinical trials requiring imaging services, including […]

Oxford, UK, 10th April 2019. Data published in a medical research study demonstrated the technical performance of multiparametric MRI technology, LiverMultiScan™, to aid in the diagnosis of liver disorders. The findings showed high precision in measuring three key biomarkers of liver disease, iron, fibro-inflammation and fat, even when using different MRI scanner models and magnetic […]

Vienna, Austria, 9th April 2019. A ground-breaking quantitative biliary imaging tool, MRCP+, will be launched at the International Liver Congress. Focusing on its utility in clinical practice, new data found in MRCP+ studies of Primary Sclerosing Cholangitis (PSC) patients will be presented by international biliary experts, including Professor Michael Manns, Dr Kris Kowdley and Dr […]

OXFORD, UK, 8th April 2019. Medical imaging expert, Perspectum Diagnostics, will present multiple abstracts at the International Liver Congress 2019 in Vienna, showcasing groundbreaking new research with LiverMultiScan®. Donna Cryer, President and CEO of the Global Liver Institute commented on the research: “As chronic liver diseases are increasingly recognised as prevalent across the globe, it […]

Oxford, England, 2 April 2019. Perspectum Diagnostics has announced a successful Innovate UK grant award to develop technology that will improve the diagnosis and monitoring of type 2 diabetes. Innovate UK’s grant will see Perspectum stratify patients with type 2 diabetes using quantitative MRI assessment of associated organs, including the liver, kidneys, pancreas, spleen and […]

San Francisco, USA, 20 Mar 2019. Perspectum has been named by Beauhurst as the fastest growing Life Science Company in the UK. Beauhurst, specialists in assessing start-ups and fast-growing British companies, released the findings earlier this month. Perspectum’s turnover growth was measured against 23,000 other companies, with results setting it in first place. This rapid […]

Oxford, UK. Feb 28: Perspectum has been selected as a Red Herring Top 100 Europe winner, at an annual award ceremony held in Amsterdam.   Red Herring Top 100 Europe enlists outstanding entrepreneurs and promising companies. It selects the award winners from approximately 1,200 privately financed companies each year in the European Region. The award recognizes […]

OXFORD, England January 23 2019 – Perspectum Diagnostics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MRCP+, the worlds most advanced biliary visualization software. Perspectum has developed quantitative MRI and AI algorithms for MRCP images to provide improved visualization of intra-hepatic ducts and measure the widths […]

OXFORD, December 21, 2018 – New research reveals 4.8% of the UK population have elevated liver iron. The study, conducted by the University of Westminster and Perspectum Diagnostics, used MRI to non-invasively assess levels of liver iron. Researchers studied the burden of liver disease from excess fat and iron storage within the UK BioBank population. […]

Creation of a major US-based network for sponsors focused on clinical development of drugs and diagnostics for patients with liver disease. San Francisco, December 13, 2018 – Perspectum Diagnostics and the SC Liver Research Consortium (SCLRC) are delighted to announce a collaboration to advance clinical development of investigational therapies. This will focus on patients with […]

OXFORD, December 11, 2018 – Perspectum have, for the second year in a row, been named as one of the fastest growing businesses in the UK, building on the success of their patient-friendly medical imaging software for liver disease developed originally in Oxford University, and now available in four continents for clinical use. Beauhurst, a […]

CHICAGO, November 25, 2018 – Perspectum Diagnostics is showcasing the latest version of LiverMultiScan and its newest product, MRCP+, at the 104th Annual Radiological Society of North America (RSNA) meeting, November 25-30, 2018 (South Hall #3975). The company is hosting two reading rooms to demonstrate the latest quantitative biomarkers for liver and hepatobiliary disorders. QIRR […]

Two Abstracts Featuring Perspectum Diagnostics’ MRCP+ Accepted for Presentation at The Liver Meeting® 2018 The clinical utility of quantitative metrics produced by MRCP+ for discriminating biliary disease was the focus of several abstracts accepted for presentation, here, at the American Association for the Study of Liver Disease’s The Liver Meeting® 2018, November 9-13, 2018 (Booth […]

New York and San Francisco, CA – August 05, 2021. Perspectum and Paige today announced a strategic business partnership to leverage quantitative and artificial intelligence (AI) based tools to empower pathologists and enhance decision-making in clinical trials. Perspectum and Paige will join forces to improve the current pathology workflow for large studies through the integration […]

Two Abstracts Featuring Perspectum Diagnostics’ LiverMultiScan Selected as Posters of Distinction SAN FRANCISCO, November 9th, 2018 – The utility of imaging biomarkers in NASH is the focus of several abstracts accepted for presentation, here, at the American Association for the Study of Liver Disease’s The Liver Meeting® 2018, November 9-13, 2018 (Booth #611).  Three abstracts […]

Oxford, UK – JULY 9, 2021. Perspectum is pleased to announce that a new prospective, observational, cohort study called Precision medicine for liver tumours with quantitative magnetic resonance imaging and whole genome sequencing (Precision1, NCT04597710) is underway. Participants with primary or secondary liver cancer will be recruited from Hampshire Hospitals NHS Foundation Trust in Basingstoke. […]

GE Healthcare and Perspectum Diagnostics invest to develop scalable AI solutions to diagnose liver disease with MRI through a newly formed consortium in collaboration with the University of Oxford. A key project for consortium will be utilizing AI in the early detection of iron overload. UK Research and Innovation will invest £10 million as part […]

Oxford, June 23, 2020. We are pleased to announce Perspectum has been awarded a grant under the NCIMI COVID Research Fund to support our recently launched COVERSCAN study, a landmark study of multi-organ phenotyping in patients recovering from COVID-19. COVERSCAN is the first study to assess the impact of COVID-19 on multi-organ health, using Perspectum’s […]

Oxford, UK – JUNE 17, 2021. Perspectum is pleased to announce that it has been successful in the latest round of the Artificial Intelligence in Health and Care Award. Phase 2 funding has been awarded for a collaborative research project designed to predict fetal growth restriction. The collaboration’s partners also include the Fetal Medicine Foundation, […]

Oxford University spin-out, Perspectum Diagnostics’ proprietary multiparametric software, LiverMultiScan, aids clinicians in the diagnosis of liver disorders and is now approved for clinical use in Singapore. Perspectum Diagnostics, a global leader in the development of medical image analysis technologies, announced today that it has received clearance by the Health Sciences Authority (HSA) for its flagship […]

We would like to congratulate Helena Thomaides-Brears, H.B. et al. for their publication success of “Incidence of complications from percutaneous biopsy in chronic liver disease: ​a​ systematic review and meta-analysis”. Liver disease is on the rise and liver biopsy remains the gold standard for the diagnosis of many liver disorders. Our latest study, a systematic review and meta-analysis of 64,356 percutaneous […]

Oxford, United Kingdom, September 10th, 2018 | New data published in PLOS One, demonstrate the utility and variability of three non-invasive liver health biomarkers, and highlight excellent reproducibility of iron-corrected T1 (cT1) in comparison to other methods. Whilst several non-invasive biomarkers have been evaluated in NASH clinical trials recently, this is the first time that […]

Oxford, UK – May 26, 2021. Perspectum announced that it has signed a strategic business partnership with Marubeni Corporation (“Marubeni”) to support entry of Perspectum’s AI diagnostic technology, called LiverMultiScan, into the Japanese market. “We are delighted to partner with Marubeni to bring LiverMultiScan to Japan” said Dr. Rajarshi Banerjee, Chief Executive Officer of Perspectum. […]

We are delighted to announce today that our flagship product, LiverMultiScan™, has received clearance as a Medical Device from the Therapeutic Goods Administration. This clearance will allow clinicians in Australia to use LiverMultiScan as part of the diagnostic pathway for patients. In Australia, imaging is a commonly used diagnostic tool for NAFLD, in particular, ultrasound. […]

Singapore, 4th May 2021 – Perspectum, in collaboration with the National Cancer Centre of Singapore (NCCS) and other partners, launch a landmark study for early detection of hepatocellular carcinoma (HCC) in high-risk individuals. Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer. Worldwide, it is the 6th most common cancer and in […]

[Oxford, UK], [July 27, 2018] An MRI-based measure, corrected T1 (cT1), could be used as a potential biomarker for liver health, a study in collaboration with Massachusetts General Hospital, Perspectum Diagnostics and the University of Westminster has found. This study involved over 2,800 subjects from the UK BioBank MRI imaging study. The UK BioBank is […]

BMJ Open publishes research demonstrating physiological basis for condition OXFORD, ENGLAND, April 26th, 2021 — New research published in BMJ Open outlines findings from a study on multiorgan impairment in individuals with persistent symptoms following recovery from COVID-19 infection— a condition referred to as long COVID. The study included characterization of organ function using global […]

Research led by two leading tertiary UK liver centres, Queen Elizabeth Hospital Birmingham and Royal Infirmary of Edinburgh, showed that multiparametric MRI performed well as a diagnostic tool to The study showed that LiverMultiScan™ had excellent test-retest reliability and good accuracy for quantifying fat and fibro-inflammatory injury in the liver. These findings also correlated well […]

OXFORD, England, April 22, 2021 – Perspectum, a commercial-stage, precision-health company developing proprietary digital technologies that enable clinicians to more accurately diagnose and monitor patients with chronic metabolic diseases, multi-organ pathologies and cancer, announced the appointment of Annalisa Jenkins, MBBS, FRCP to its Board of Directors. Dr. Jenkins brings extensive expertise in advancing biopharma programs […]

Breakthrough non-invasive liver imaging helps identify patients at increased risk of severe disease Oxford, UK – March 29th 2021. New research published this month in Frontiers in Medicine (Gastroenterology) reveals that individuals with both obesity and severe fatty liver are five times more likely to require hospitalization for the illness. The non-invasive liver imaging technology […]

Recent work from Christopher Bradley and colleagues at Nottingham University demonstrates the feasibility of a quantitative T1 biomarker to accurately evaluate changes in cirrhosis and predict liver-related clinical outcomes. In this 107 person population study, consisting of patients with compensated cirrhosis, decompensated cirrhosis, and healthy volunteers, T1 was found to be significantly higher in compensated […]

Oxford March 3rd 2021. LiverMultiScan®’s cT1® is the best predictor of autoimmune hepatitis (AIH) disease activity, as shown in a recent publication, which demonstrates its potential to influence clinical treatment and so reduce likelihood of disease progression. AIH is a chronic liver disease characterised by liver inflammation, which affects patients throughout their entire lives.  Patients […]

“One of the keys to long-term biotech investing is finding the big winners and riding them to huge gains, writes Medical Technology Stock Letter editor John McCamant and frequent MoneyShow.com contributor.” Over the last year and a quarter, our subscribers have been enjoying incredible gains with the Four Horsemen: Madrigal MDGL-3196 EASL abstracts released – […]

Diagnostic imaging company helps providers better assess patient conditions, pursue targeted treatments and achieve greater patient outcomes. OXFORD, UK, March 1, 2021. Alantra today announces it has awarded Perspectum the top spot in its 2021 Pharma Fast 50 technology category rankings and third place in the overall rankings. Each year, Alantra releases its Pharma Fast […]